|
|
|
| The 6th mRNA-Based Therapeutics Summit returns to Boston as the leading forum accelerating mRNA discoveries into scalable, clinically validated therapies. Amid rapid deal making and progress across in vivo CAR T, gene editing, and cancer immunotherapy, 300+ leaders from pharma, biotech, and regulators unite. With three scientific tracks plus new AI driven design and next gen delivery focus days, this flagship event drives innovation, partnerships, and pipeline acceleration. |
|
|
|
|
By Anna Rose Welch, editorial & community director, Advancing RNA | A few weeks ago, I had the chance to sit down with OPT Congress speaker Phil Baran, Richard Lerner Chair Professor, Department of Chemistry, Scripps Research. Baran was slated to (and did) present a keynote on the innovations shaping the next generation of oligo synthesis. Here, I share the biggest takeaways I had from our conversation, touching on how he sees the science of oligo chemistry and manufacturing advancing in the near and far future. | |
|
|
|
|
|
|
|
| Validation Of mRNA Concentration Determination | Webinar | Aldevron | mRNA-based therapeutics require comprehensive analytical testing to meet regulatory requirements. Optimize processes and ensure fast and reliable results as you bring your product to market. |
|
|
|
|
| A New Center For Continuous mRNA Manufacturing | Article | Recipharm Advanced Bio | Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies. |
|
|
|
|
|
|
|
.png){kind=logo}
